DV
Dividend Vision

LUNG — Pulmonx Corp

Pulmonx Corp (LUNG)

Total return is -93.8% over the past 5.9 years, 242.9 points behind SPY at 149.1%. Its deepest 1-year drawdown was 55.0%.

Pulmonx Corporation is a commercial-stage medical technology company that develops minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease. The company's primary offering is the Zephyr Endobronchial Valve, along with supporting diagnostic and assessment systems including the Chartis Pulmonary Assessment System and LungTraX Platform, a cloud-based analysis service for patient identification and treatment planning. Pulmonx does not currently distribute dividends and is primarily oriented toward investors seeking exposure to medical device innovation rather than current income generation.

LUNG key facts

Asset type
Stock
Asset class
Equity
Inception date
10/01/2020
Last close
$2.42
Market cap
$53,641,248
Average volume
857500.0
Beta
0.306
Payout ratio
0.0
Forward P/E
28.3286
EPS
$-1.30